Effective March 31, 2019, FDA will begin operational implementation of an agency reorganization. FDA’s reorganization reflects the agency’s commitment to modernizing its structure to advance its mission to protect and promote public health, and to meet the challenges of rapid innovation across the industries regulated by FDA. The FDA’s reorganization will realign several entities across the agency to promote strategic priorities, and will elevate the role of the centers, offices and field forces.
This organization chart reflects the new structure under which FDA will operate.
The Office of Medical Products and Tobacco provides high-level coordination and leadership across the centers for drug, biologics, medical devices, and tobacco products. The office also oversees the agency's special medical programs.